Home » Stocks » RNLX

Renalytix AI PLC (RNLX)

Stock Price: $25.23 USD 2.43 (10.66%)
Updated Mar 1, 2021 12:59 PM EST - Market open
Market Cap 862.56M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 69.84M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $25.23
Previous Close $22.80
Change ($) 2.43
Change (%) 10.66%
Day's Open 23.00
Day's Range 23.00 - 26.04
Day's Volume 35,740
52-Week Range 9.91 - 29.12


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatmen...

GlobeNewsWire - 6 days ago

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), the artificial intelligence-enabled in vitro diagnostics company, focu...

GlobeNewsWire - 1 month ago

Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidne...

Zacks Investment Research - 1 month ago

Renalytix AI (RNLX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs...

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical managem...

PRNewsWire - 2 months ago

NEW YORK, Dec. 2, 2020 /PRNewswire/ --The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in t...

Benzinga - 3 months ago

AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with ca...

Other stocks mentioned: AIM, ANPC

About RNLX

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed produc... [Read more...]

Diagnostics & Research
IPO Date
Jul 17, 2020
James R. McCullough M.B.A.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements